CHA ÀÇ°úÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • À¯ÁØȯ
  • ¼Ò ¼Ó: ºÐ´çÂ÷º´¿ø
  • Àü¹®ºÐ¾ß : ¿°Áõ¼ºÀåÁúȯ, ´ëÀå¾Ï, Ä¡·á³»½Ã°æ
  • Á÷ À§: ºÎ±³¼ö
  • ¸Þ ÀÏ: ºñ°ø°³
  • Àü È­: 1577-4488
  • ÆÑ ½º:
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßž·Î 59
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ
57 (±¹¿Ü)SCI 2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B
56 (±¹³»)KCIÈĺ¸ À§¾Ï¿¡¼­ Microsatellite Instability¿Í Thymidylate SynthaseÀÇ »ó°ü°ü°è
55 (±¹³»)KCI ³»½Ã°æÀ¸·Î Áø´ÜÇÑ »óÀå°£¸·µ¿¸ÆÁõÈıº°ú ÀÌ¿¡ µ¿¹ÝµÈ À§¼®ÀÇ ¾Æ¸£°ï ÇöóÁ ÀÀ°í ¼ÒÀÛ¼úÀ» ÀÌ¿ëÇÑ ºÐ¼â Á¦°Å Ä¡·á 1¿¹
54 (±¹¿Ü)SCI STAT3 expression in gastric cancer indicates a poor prognosis
53 (±¹³»)SCIE Fatal Biliary-Systemic Air Embolism during Endoscopic Retrograde Cholangiopancreatography: A Case with Multifocal Liver Abscesses and Choledochoduodenostomy
52 (±¹¿Ü)SCI Methylenetetrahydrofolate Reductase (MTHFR) and Methionine Synthase Reductase (MTRR) Gene Polymorphisms as Risk Factors for Hepatocellular Carcinoma in a Korean Population
51 (±¹³»)KCI µÚÁ¾°Ýµ¿¿¡¼­ ¹ß»ýÇÑ °Å´ë ÆòÈ° ±ÙÀ°Á¾ÀÇ 1¿¹
50 (±¹³»)KCI ¸¸¼º BÇü°£¿° ȯÀÚ¿¡¼­ hepatitis B core antigenÀÇ ¹ßÇö°ú ºÐÆ÷ À§Ä¡¿¡ µû¸¥ ¶ó¹ÌºÎµòÀÇ Ä¡·á ¹ÝÀÀ
49 (±¹³»)KCI Á¤»ó °£±â´É ¼öÄ¡¸¦ º¸ÀÌ´Â ºñ¾ËÄÚ¿ÃÁö¹æ°£ ȯÀÚÀÇ ÀÓ»óƯ¡
48 (±¹¿Ü)SCI Selection of precore mutants during lamivudine treatment in patients with chronic hepatitis B
ÀÌÀüÆäÀÌÁö À̵¿ 31 32 33 34 35 36 37 38 39 40 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾ÇÕ°Ç°­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729